UK Study Reveals Surfactant Treatment Offers No Benefit for Severe Bronchiolitis in Infants
A landmark UK clinical trial, the Bronchiolitis Endotracheal Surfactant Study (BESS), has revealed that surfactant treatment doesn’t improve outcomes for babies on life support with severe bronchiolitis. The findings, published on March 21, 2026, in The Lancet Respiratory Medicine, challenge current practices and highlight the urgent need for alternative therapies for this common, and sometimes life-threatening, respiratory illness.
Understanding Bronchiolitis and Surfactant’s Role
Bronchiolitis, most frequently caused by respiratory syncytial virus (RSV), inflames the small airways in the lungs, making breathing difficult. It primarily affects babies under one year old, with premature infants facing the highest risk of severe complications. Babies with bronchiolitis often experience reduced levels of surfactant, a substance that helps retain the lungs open.
Surfactant is routinely used to treat breathing difficulties in premature babies, leading researchers to investigate whether it could likewise benefit infants hospitalized with severe bronchiolitis. The BESS trial, the largest of its kind, involved 232 critically ill babies across 15 hospitals in England, Scotland, and Northern Ireland.
Key Findings of the BESS Trial
Despite the logical rationale, the study found that administering surfactant did not reduce the amount of time babies needed to remain on a ventilator. Professor Calum Semple OBE, lead researcher from the University of Liverpool and Alder Hey Children’s NHS Foundation Trust, stated the treatment was safe but “didn’t create any difference to how long babies stayed on ventilators.”
The BESS trial ran for six winter seasons, from 2019 to 2024, providing a robust dataset for analysis. The research was funded by the UKRI Medical Research Council (MRC), the National Institute for Health and Care Research (NIHR), and Chiesi Farmaceutici SpA, Italy.
The Rise of RSV Vaccination and Future Directions
While the BESS trial didn’t demonstrate a benefit from surfactant, there is positive news in the fight against bronchiolitis. A vaccine is now available for pregnant women, offering protection to their newborns against severe RSV infection. Professor Semple urges expectant mothers to accept this vaccine.
Researchers emphasize that surfactant therapy remains vital for premature babies. The focus now shifts to exploring targeted treatments specifically for bronchiolitis and continuing research into better care for affected infants.
What Does This Mean for Parents and Healthcare Providers?
The BESS trial results provide clarity for clinicians managing severe bronchiolitis. While surfactant isn’t a solution, it doesn’t preclude the use of supportive care – oxygen and fluids – which remain the standard treatment for most cases. The availability of the RSV vaccine offers a proactive step to protect vulnerable newborns.
Did you understand? Bronchiolitis is the leading cause of infant hospital admissions in the UK during winter, affecting around twenty-five thousand babies annually.
Frequently Asked Questions
Q: What is surfactant?
A: Surfactant is a substance in the lungs that helps keep the air sacs open, making breathing easier.
Q: What causes bronchiolitis?
A: The most common cause of bronchiolitis is respiratory syncytial virus (RSV).
Q: Is there a cure for bronchiolitis?
A: Currently, there is no specific cure for bronchiolitis. Treatment focuses on supportive care.
Q: What is the RSV vaccine?
A: The RSV vaccine is offered to pregnant women to protect their newborns from severe bronchiolitis.
Pro Tip: Early detection and prompt medical attention are crucial for managing bronchiolitis. Contact your healthcare provider if your baby exhibits signs of respiratory distress.
Learn more about bronchiolitis and RSV prevention from the NHS website.
Have questions about bronchiolitis or your baby’s health? Share your thoughts in the comments below!
